SOHO 2021 | CAR-T therapy for high-risk MCL patients
Michael L. Wang, MD, MD Anderson Cancer Center, Houston, TX, discusses the use of chimeric antigen receptor T-cell (CAR-T) therapy for patients with high-risk mantle cell lymphoma (MCL) in the frontline setting. High-risk factors include blastoid or pleomorphic MCL, complex karyotype, TP53 mutations and high KI-67 proliferation indices. Clinical trials investigating CAR-T therapy for patients with high-risk MCL are currently underway. CAR-T therapy is already being utilized in clinical practice as a second-line treatment for high-risk MCL. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Michael Wang, MD, PhD, has participated in consultancy work with AstraZeneca, Bayer Healthcare, BeiGene, CSTone, DTRM Biopharma (Cayman) Limited, Epizyme, Genentech, InnoCare, Janssen, Juno, Kite Pharma, Loxo Oncology, Miltenyi Biomedicine GmbH, Oncternal, Pharmacyclics and VelosBio; has received research funding from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Innocare, Janssen, Juno, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics and VelosBio; has received honoraria from Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, CAHON, Chinese Medical Association, Clinical Care Options, Dava Oncology, Epizyme, Hebei Cancer Prevention Federation, Imbruvica, Imedex, Janssen, Kite Pharma, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharmaceuticals, OMI, Physicians Education Resources (PER), Scripps, The First Afflicted Hospital of Zhejiang University and BGICS.
